신성 고혈압 백서의 Renin Secretion 조절의 특성

제갈영종,조경우,Jegal, Young-J.,Cho, Kyung-W. 대한생리학회 1986 대한생리학회지 Vol.20 No.1

It has long been suggested that the change of renin-angiotensin system is responsible for the increased arterial blood pressure in the experimental hypertension. But the exact nature of the cause and maintenance of early and late Phase of renal hypertension is still controversial. Increased renin-angiotensin system has been suggested. To clarify the altered renin-angiotensin system in the early phase of two kidney one clip Goldblatt hypertension(2K1C GH), experiments were carried out in the rats of 3,7, and 14 days of 2K1C GH rats, sham-operated, and control rats. Responses of the plasma renin activity to the intravenous infusion of L-isoproterenol were dose-dependent. Responses of the plasma renin activity to the intravenous L-isoproterenol in 2K1C GH rats were not different from sham-operated control rats. Hypotensive responses of the 2K1C GH rats were not different from sham-operated rats. Suppression by intravenous infusion of angiotensin II of plasma renin activity showed a dose-dependent manner. Suppression by angiotensin ll of plasma renin activity was attenuated or abolished in the early phase of 2K1C GH rats. Intravenous infusion of arginine vasopressin(AVP) showed a dose-dependent suppression of plasma renin activity, Attenuated responses by AVP of plasma renin activity were noticed in the early phase of 2K1C GH rats. These results suggest that the altered renin-angiotensin system in the early phase of the two kidney one clip Goldblatt hypertension may be caused by failure of the short loop negative feedback control mechanism.

유방의 수질암

제갈영종,조용근,윤정한,김종순 中央醫學社 1997 中央醫學 Vol.62 No.7

Medullar carcinoma of breast which have been referred to as solid circumscribed carcinoma represents some characteristics different from ductal carcinoma in breast. To reveal these characteristics is important in order to manage more accurately the patients with medullar carcinoma. However the characteristics of Korean medullar breast carcinoma were not clarified yet. So we analyzed the our experience for medullar carcinoma to determine its clinic pathological characteristics. We evaluated 16 patients from January, 1989 to December, 1996. The results were follows ; Medullar carcinoma was developed at rate of 4.3 % in breast cancers. Mean age was 46.7 years and most of them(62.5 %) was belonged to stage La. Negative expression of steroid receptor was more common and Diploidic pattern was common in flow cytometric study, compared with ductal carcinomas. All patients in this study was alive without recurrence in follow-up period(4 months 5 years). In conclusion, we can suggest that medullar carcinoma of breast has a less aggressive behavior than invasive ductal carcinoma in spite of some bizarre histological characteristics.

Etoposide와 Cisplatin의 병합요법에 의한 재발유방암의 치료

제갈영종,윤정한,차정곤 中央醫學社 1999 中央醫學 Vol.64 No.1

New Cephem계 항생제 Meicelin^(�)(Cefminox Sodium)주의 임상적 유용성 평가

제갈영종,윤정한,조재식 中央醫學社 1993 中央醫學 Vol.58 No.4

It was reported that Meicelin� is a cephamycin antibiotic possessing broad spectrum anti-bacterial activity from gram positive and gram negative to anaerobic bacteria. So, we tried to evaluate the clinical efficacy of Meicelin� in diverse typed surgical in fections. The results were follows. 1. The evaluated infections objects were small bowel perforation 5 cases, cholangitis 5 cases, acute suppurative cholecystitis 4 cases, peptic ulcer perforation 3 cases, liver abscess 2 cases, perforative appendicitis 2 cases, wound infection 2 cases, and strangulated ileus 1 case. 2. Overall effective rate in objected cases following administration of Meicelin� was 88%. 3. The cultured organisms in cases showing effective clinical responses were revealed E. coli, bacteroides, enterococcus, proteus mirabilis, klebsiella oxytoca, and aeromonas hydrophilia. 4. The cultured organisms in cases showing unsatiffactory responses were streptococcus viridans and pseudomonas aeruginosa. 5. No significant side-effects were noted following administration of Meicelin�., In conclusion, Meicelin� can be effectively used in various surgical infections without significant adverse reactions.

제30차 학술대회 : 126. Keflin 의 복강내 주입에 대한 임상적 연구

제갈영종,조영국 () 대한외과학회 1978 대한외과학회 학술대회자료집 Vol.- No.-

65. Etoposide와 Cisplatin의 병합요법에 의한 재발유방암의 치료

제갈영종,윤정한,차정곤 대한외과학회 1998 대한외과학회 학술대회 초록집 Vol.1998 No.5

내분비 췌장외과 분야의 20세기 회고 및 21세기 전망

제갈영종,Young Jong Jegal 대한갑상선-내분비외과학회 2001 The Koreran journal of Endocrine Surgery Vol.1 No.1

Keflin 의 복강내 주입에 대한 임상적 연구

제갈영종,조영국 대한외과학회 1979 Annals of Surgical Treatment and Research Vol.21 No.1

40세이하의 여성에서의 유방종물

제갈영종 中央醫學社 1991 中央醫學 Vol.56 No.3

The breast mass in young women less than 40 age is a source of great concern to both patients and examining surgeon. Expectant conservative treatment with delay in diagnosis is a problem for surgeon to know actual risk of the breast cancer and the traumatic biopsy accompanied with frequent radiologic examination generates a great deal of anxiety to the patient. So, a clinical study was made on 633 cases of breast mass that had been diagnosed from Jan. 1980 through May 1990 at the Department of Surgery, College of Medicine, Chonnam University to identify a possible diagnostic standard of the breast mass in relation with age. The results were as follows: Under the age of 20, all of the breast masses were benign and 74% of the masses were fibroadenoma. In patients aged 21 to 25, almost were fibroadenoma (45.6 %) and fibrocystic disease (44.5 %) but minority (4.4 %) was malignancy. In patient aged 26 to 30, 31 to 35, and 36 to 40, fibrocystic disease was the most frequent lesion and the rate of the malignancy increased according to aging (6 %, 12.5 %, 17.8 %). In conclusion, the breast mass under the age 20 was required to be managed conservatively. But the incidence of malignancy increased with the age of the patient and the possibility of malignancy should be excluded with adequate diagnostic procedures.

Medroxyprogesterone(Farlutal^(�))을 이용한 재발성 유방암의 치료

제갈영종,윤정한,정상우 中央醫學社 1995 中央醫學 Vol.60 No.1

Endocrine therapy is the oldest form of systemic treatment of advanced breast cancer and consisted of ablation therapy and adding agents which reduce the estrogen effect. Improvements in endocrine therapy have been achieved by better ways of selecting patients likely to respond, by advent of new drugs with less-side effects and better understanding of the mechanism of action. Progestin as an adding agent was shown to have antiestrogen effects and have a possibility as an effective treatment modality for breast cancer. Although many reports at early stage showed its therapeutic effects was minimal due to short duration of response and unremarkable results, progestin has become a promising endocrine modality for the treatment of metastatic breast cancer through the developments of new synthetic progestins and the use with proper dosage. So, we tried to evaluate the therapeutic results of Medroxyprogesterone(Farlutal), one of the most widely used synthetic progestins, in management of metastatic breast cancer patients. The results were follows 1. The number of patients in this study was 9 cases which had 10 recurrent organ sites consisted of 7 bones, 1 lung, 1 liver and 1 lymph nodes. 2. The therapeutic response rate with Farlutal^(�) was marked in cases having bone metatstasis(85.7 %). 3. Following administration of Farlutal^(�), improvement of subjective symptoms such as pain relief, well-being sense and increased appetite were notified in majority of the patients. 4. Other toxic side-effects than weight gain in 3 cases and vaginal bleeding in 1 case were not noted. So, We concluded Farlutal^(�) is a safe and effective hormonal agent that has marked therapeutic efficacy in cases with bone metastasis and improves many disabling complaints in patients with metastatic breast cancer.